AJANTA PHARMA LIMITED (AJANTPHARM) financials

AJANTA PHARMA LIMITED (AJANTPHARM) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).

Market Cap: ₹41,599Cr.
Current Price: ₹3,329
Stock P/E: 41.3
ROE: 24.0%
ROCE: 31.0%
Book Value: ₹338
Dividend Yield: 0.96%
52W High / Low: ₹3,797/2,382

In Jun 2026, AJANTA PHARMA LIMITED (AJANTPHARM) reported sales ₹1,489 Cr and net profit ₹315 Cr.

Annual TTM: sales ₹5,126 Cr, net profit ₹1,007 Cr.

Shareholding: Promoters 63.47% (Sep 2026), FIIs 7.62% (Sep 2026), DIIs 21.94% (Sep 2026), Government 0.00% (Sep 2026), Public 6.96% (Sep 2026).

AJANTPHARM quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1,129	1,102	1,014	1,209	1,220	1,207	1,211	1,489
Expenses	826	766	764	879	931	866	972	1,092
Operating Profit	303	336	250	329	290	341	238	397
OPM %	27%	31%	25%	27%	24%	28%	20%	27%
Other Income	40	33	18	41	75	26	63	71
Interest	1	2	1	1	1	2	-1	1
Depreciation	33	35	39	40	42	42	44	43
Profit before tax	309	332	228	329	322	322	258	423
Tax %	24%	24%	15%	22%	22%	24%	23%	26%
Net Profit	235	252	193	255	250	245	197	315
EPS in Rs	18.81	20.21	15.49	20.41	19.97	19.61	15.79	25.25
Raw PDF	—	—	—	—	—	—	—	—

AJANTPHARM profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	2,196	2,719	3,141	3,411	3,971	4,322	4,846	5,126
Expenses	1,664	1,800	2,246	2,710	2,852	3,117	3,646	3,861
Operating Profit	533	919	895	701	1,119	1,205	1,200	1,265
OPM %	24%	34%	28%	21%	28%	28%	25%	25%
Other Income	180	102	136	131	116	119	203	235
Interest	9	7	9	5	7	5	3	3
Depreciation	91	111	121	127	132	140	169	172
Profit before tax	613	902	901	700	1,097	1,180	1,231	1,325
Tax %	28%	25%	20%	20%	26%	22%	23%	—
Net Profit	441	676	720	559	807	917	947	1,007
EPS in Rs	33.70	52.05	56.20	43.61	63.00	73.40	75.78	80.62
Dividend Payout %	26%	12%	11%	16%	80%	38%	37%	—

AJANTPHARM balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	18	18	17	17	25	25	25	25
Reserves	2,125	2,444	2,868	3,152	3,221	3,388	3,600	4,198
Borrowings	0	23	26	20	33	31	31	35
Other Liabilities	379	564	621	591	1,025	773	898	1,058
Total Liabilities	2,522	3,049	3,532	3,780	4,305	4,217	4,554	5,317
Fixed Assets	1,162	1,449	1,519	1,492	1,484	1,465	1,742	1,845
CWIP	261	131	108	153	209	256	176	258
Investments	83	86	157	165	553	367	482	606
Other Assets	1,015	1,383	1,748	1,970	2,058	2,129	2,154	2,608
Total Assets	2,522	3,049	3,532	3,780	4,305	4,217	4,554	5,317

AJANTPHARM cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	312	301	467	542	736	735	1,054	804
Cash from Investing Activity	-137	-116	-163	-66	-501	105	-350	-400
Cash from Financing Activity	-181	-134	-269	-457	-105	-1,048	-716	-360
Net Cash Flow	-6	51	35	19	130	-207	-12	45
Free Cash Flow	-27	75	313	414	561	595	737	437
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	86%	82%	72%	82%	123%	88%	111%	91%

AJANTPHARM shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	66.26%	66.26%	66.26%	66.25%	66.25%	66.25%	63.49%	63.47%
FIIs	9.26%	8.86%	8.86%	8.53%	7.97%	8.26%	7.68%	7.62%
DIIs	17.02%	17.48%	17.50%	17.90%	18.58%	18.36%	21.80%	21.94%
Government	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.00%	0.00%
Public	7.45%	7.38%	7.38%	7.32%	7.20%	7.14%	7.03%	6.96%
No. of Shareholders	66,896	70,827	68,882	67,785	65,409	67,955	65,296	61,923

AJANTPHARM key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	87	122	105	121	105	111	104	103
Inventory Days	386	240	317	278	248	229	267	286
Days Payable	173	166	159	120	128	130	132	160
Cash Conversion Cycle	300	195	264	279	225	210	238	229
Working Capital Days	132	132	138	153	92	130	116	119
ROCE %	25%	27%	34%	30%	21%	32%	33%	31%

AJANTPHARMUpdated 19 Oct 2026, 5:03

Ajanta Pharma Limited

AJANTPHARMUpdated 19 Oct 2026, 5:03

Market Cap

₹41,599Cr.

Current Price

₹3,329

High / Low

₹3,797/2,382

Stock P/E

41.3

ROE24.0%

ROCE31.0%

Book Value₹338

Face Value₹2.00

Dividend Yield0.96%

About

Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	1015	1	738	31	32	275	23	212	16.55
Sep 2023	945	2	672	52	33	290	27	212	16.57
Dec 2023	1085	2	758	14	33	305	28	220	17.18
Mar 2024	926	1	699	34	33	226	28	163	12.7
Jun 2024	1077	1	761	28	33	311	24	236	18.9
Sep 2024	1129	1	826	40	33	309	24	235	18.81
Dec 2024	1102	2	766	33	35	332	24	252	20.21
Mar 2025	1014	1	764	18	39	228	15	193	15.49
Jun 2025	1209	1	879	41	40	329	22	255	20.41
Sep 2025	1220	1	931	75	42	322	22	250	19.97
Dec 2025	1207	2	866	26	42	322	24	245	19.61
Mar 2026	1211	-1	972	63	44	258	23	197	15.79
Jun 2026	1489	1	1092	71	43	423	26	315	25.25

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	1356	5	884	27	49	445	31	306	23.21
Mar 2016	1574	4	1044	80	43	563	25	422	31.97
Mar 2017	1804	1	1166	63	59	641	22	500	37.86
Mar 2018	1825	0	1279	73	57	562	24	428	32.39
Mar 2019	1773	0	1291	102	70	513	24	392	29.93
Mar 2020	2196	9	1664	180	91	613	28	441	33.7
Mar 2021	2719	7	1800	102	111	902	25	676	52.05
Mar 2022	3141	9	2246	136	121	901	20	720	56.2
Mar 2023	3411	5	2710	131	127	700	20	559	43.61
Mar 2024	3971	7	2852	116	132	1097	26	807	63
Mar 2025	4322	5	3117	119	140	1180	22	917	73.4
Mar 2026	4846	3	3646	203	169	1231	23	947	75.78
TTM	5126	3	3861	235	172	1325	—	1007	80.62

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	63.47%
FIIs	7.62%
DIIs	21.94%
Public	6.96%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Dec 2023	66.22%	9.11%	16.67%	0%	8%
Mar 2024	66.22%	8.54%	17.48%	0%	7.76%
Jun 2024	66.27%	8.36%	17.41%	0.01%	7.94%
Sep 2024	66.26%	9.11%	17.09%	0.01%	7.51%
Dec 2024	66.26%	9.26%	17.02%	0.01%	7.45%
Mar 2025	66.26%	8.86%	17.48%	0.01%	7.38%
Jun 2025	66.26%	8.86%	17.5%	0.01%	7.38%
Sep 2025	66.25%	8.53%	17.9%	0.01%	7.32%
Dec 2025	66.25%	7.97%	18.58%	0.01%	7.2%
Mar 2026	66.25%	8.26%	18.36%	0.01%	7.14%
Jun 2026	63.49%	7.68%	21.8%	0%	7.03%
Sep 2026	63.47%	7.62%	21.94%	0%	6.96%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	18	769	71	229	1086	271	170	77	568	1086
Mar 2016	18	1114	68	214	1414	433	240	94	647	1414
Mar 2017	18	1486	0	245	1749	573	339	199	638	1749
Mar 2018	18	1914	0	360	2292	1037	61	201	993	2292
Mar 2019	18	2125	0	379	2522	1162	261	83	1015	2522
Mar 2020	18	2444	23	564	3049	1449	131	86	1383	3049
Mar 2021	17	2868	26	621	3532	1519	108	157	1748	3532
Mar 2022	17	3152	20	591	3780	1492	153	165	1970	3780
Mar 2023	25	3221	33	1025	4305	1484	209	553	2058	4305
Mar 2024	25	3388	31	773	4217	1465	256	367	2129	4217
Mar 2025	25	3600	31	898	4554	1742	176	482	2154	4554
Mar 2026	25	4198	35	1058	5317	1845	258	606	2608	5317

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	263	-146	-101	16
Mar 2016	277	-139	-128	9
Mar 2017	537	-340	-198	-1
Mar 2018	219	-201	-1	18
Mar 2019	312	-137	-181	-6
Mar 2020	301	-116	-134	51
Mar 2021	467	-163	-269	35
Mar 2022	542	-66	-457	19
Mar 2023	736	-501	-105	130
Mar 2024	735	105	-1048	-207
Mar 2025	1054	-350	-716	-12
Mar 2026	804	-400	-360	45

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	65	81	68	86	87	122	105	121	105	111	104	103
Inventory Days	147	167	149	290	386	240	317	278	248	229	267	286
Days Payable	104	128	121	193	173	166	159	120	128	130	132	160
Cash Conversion Cycle	108	121	96	183	300	195	264	279	225	210	238	229
Working Capital Days	55	83	73	115	132	132	138	153	92	130	116	119
ROCE %	60%	55%	48%	33%	25%	27%	34%	30%	21%	32%	33%	31%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of AJANTA PHARMA LIMITED (AJANTPHARM)?

The reported market capitalisation for AJANTA PHARMA LIMITED (AJANTPHARM) is ₹41,599Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of AJANTPHARM?

The current price shown for AJANTA PHARMA LIMITED (AJANTPHARM) on Fincrux is ₹3,329 with a 52-week high/low of ₹3,797/2,382.

What is the P/E ratio of AJANTA PHARMA LIMITED (AJANTPHARM)?

The stock P/E for AJANTA PHARMA LIMITED (AJANTPHARM) is 41.3 on Fincrux, with ROE at 24.0% and ROCE at 31.0%.

What were AJANTPHARM latest quarterly results?

For Jun 2026, AJANTA PHARMA LIMITED (AJANTPHARM) reported sales ₹1,489 Cr and net profit ₹315 Cr (figures in ₹ crore unless noted).

What are AJANTPHARM annual sales and net profit?

For TTM, AJANTA PHARMA LIMITED (AJANTPHARM) shows sales of ₹5,126 Cr and net profit of ₹1,007 Cr on the Fincrux profit & loss statement.

Who owns AJANTA PHARMA LIMITED (AJANTPHARM)?

Latest shareholding for AJANTA PHARMA LIMITED (AJANTPHARM) on Fincrux: Promoters 63.47% (Sep 2026), FIIs 7.62% (Sep 2026), DIIs 21.94% (Sep 2026), Government 0.00% (Sep 2026), Public 6.96% (Sep 2026).

Where can I find AJANTA PHARMA LIMITED (AJANTPHARM) financials?

AJANTA PHARMA LIMITED (AJANTPHARM) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show AJANTPHARM balance sheet and cash flow?

Yes. The AJANTA PHARMA LIMITED (AJANTPHARM) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 19 October 2026 at 5:03